<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Problems of Social Hygiene, Public Health and History of Medicine</journal-id><journal-title-group><journal-title>Problems of Social Hygiene, Public Health and History of Medicine</journal-title></journal-title-group><issn publication-format="print">0869-866X</issn><issn publication-format="electronic">2412-2106</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1114</article-id><article-id pub-id-type="doi">10.32687/0869-866X-2022-30-6-1328-1330</article-id><article-categories><subj-group subj-group-type="heading"><subject>Научная статья</subject></subj-group></article-categories><title-group><article-title>The characteristics of restrictive listings of medications: the position of orphan medical preparations</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Komarov</surname><given-names>I. A.</given-names></name><bio></bio><email>iliya_komarov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">N. A. Semashko National Research Institute of Public Health</aff><pub-date date-type="epub" iso-8601-date="2022-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2022</year></pub-date><volume>30</volume><issue>6</issue><fpage>1328</fpage><lpage>1330</lpage><history><pub-date date-type="received" iso-8601-date="2022-12-21"><day>21</day><month>12</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2022,</copyright-statement><copyright-year>2022</copyright-year></permissions><abstract>In the Russian Federation, the regulations on making out restrictive listings of medications were established as separate Government Order in 2014. Since this moment, the procedure of listing revision underwent various changes. The last revisions of this legal document contained several amendments regarding orphan medications. So, in last version the rating scale included separate component related to these medications. This indicates at unique characteristics of orphan medications that not allow to consider them along with other medications. The article covers main stages of drug list forming procedures of making out restrictive listings of medications in the light of how available methodology is adapted to be applied to orphan medications.</abstract><kwd-group xml:lang="en"><kwd>public health</kwd><kwd>health care</kwd><kwd>rare diseases</kwd><kwd>orphan medications</kwd><kwd>listing</kwd><kwd>medical care</kwd><kwd>patients</kwd><kwd>legal regulation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>общественное здоровье</kwd><kwd>здравоохранение</kwd><kwd>редкие заболевания</kwd><kwd>орфанные лекарственные препараты</kwd><kwd>перечни</kwd><kwd>медицинская помощь</kwd><kwd>пациенты</kwd><kwd>законодательство</kwd><kwd>нормативно-правовое регулирование</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Taruscio D., Vittozzi L., Stefanov R. National plans and strategies on rare diseases in Europe. Ad. Exper. Med. Biol. 2010;686:475-91.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Miller K. L., Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J. Rare Dis. 2018;183(13):1-8.</mixed-citation></ref></ref-list></back></article>
